Emily Brooks1, Susan E Tett2, Nicole M Isbel3,4, Brett McWhinney5, Christine E Staatz2. 1. School of Medicine, The University of Queensland, Brisbane, QLD, 4006, Australia. brooks.ek@gmail.com. 2. School of Pharmacy, The University of Queensland, Brisbane, QLD, 4006, Australia. 3. School of Medicine, The University of Queensland, Brisbane, QLD, 4006, Australia. 4. Department of Nephrology, The Princess Alexandra Hospital, Brisbane, QLD, Australia. 5. Pathology Queensland, Royal Brisbane and Women's Hospital, Brisbane, QLD, Australia.
Abstract
BACKGROUND AND OBJECTIVES: Mycophenolic acid (MPA) is commonly used following renal transplant. Saliva MPA concentrations may reflect the pharmacologically active form of MPA in plasma. Therapeutic drug monitoring using saliva is convenient and non-invasive. This study examined the correlation between total and free plasma and saliva MPA concentrations following enteric-coated mycophenolate sodium (EC-MS) administration in renal transplant recipients. METHODS: Total and free plasma and saliva MPA concentrations were measured simultaneously in 20 adult renal transplant recipients 1-2 months' post-transplant. Thirteen samples were taken pre-dose and at specified time points up until 12 h post-dose. RESULTS: When considering all time points, correlation between total plasma and saliva MPA was r2 = 0.51 and between free plasma and saliva MPA concentrations r2 = 0.41. The correlation between total plasma MPA area under the concentration-time curve (AUC) or free plasma AUC and saliva MPA AUC was r2 = 0.25 and r2 = 0.13, respectively. The correlation between total plasma MPA AUC and total plasma MPA trough (C0) concentrations was r2 = 0.51, and between total plasma MPA AUC and saliva MPA trough concentrations, r2 = 0.03. CONCLUSIONS: Measurement of MPA concentration in saliva cannot currently replace plasma measurement for therapeutic drug monitoring of MPA following EC-MS administration. Additional studies are required to examine the relationship between MPA saliva concentrations and patient outcomes.
BACKGROUND AND OBJECTIVES:Mycophenolic acid (MPA) is commonly used following renal transplant. Saliva MPA concentrations may reflect the pharmacologically active form of MPA in plasma. Therapeutic drug monitoring using saliva is convenient and non-invasive. This study examined the correlation between total and free plasma and saliva MPA concentrations following enteric-coated mycophenolate sodium (EC-MS) administration in renal transplant recipients. METHODS: Total and free plasma and saliva MPA concentrations were measured simultaneously in 20 adult renal transplant recipients 1-2 months' post-transplant. Thirteen samples were taken pre-dose and at specified time points up until 12 h post-dose. RESULTS: When considering all time points, correlation between total plasma and saliva MPA was r2 = 0.51 and between free plasma and saliva MPA concentrations r2 = 0.41. The correlation between total plasma MPA area under the concentration-time curve (AUC) or free plasma AUC and saliva MPA AUC was r2 = 0.25 and r2 = 0.13, respectively. The correlation between total plasma MPA AUC and total plasma MPA trough (C0) concentrations was r2 = 0.51, and between total plasma MPA AUC and saliva MPA trough concentrations, r2 = 0.03. CONCLUSIONS: Measurement of MPA concentration in saliva cannot currently replace plasma measurement for therapeutic drug monitoring of MPA following EC-MS administration. Additional studies are required to examine the relationship between MPA saliva concentrations and patient outcomes.
Authors: Susan E Tett; Franck Saint-Marcoux; Christine E Staatz; Merce Brunet; Alexander A Vinks; Masatomo Miura; Pierre Marquet; Dirk R Kuypers; Teun van Gelder; Dario Cattaneo Journal: Transplant Rev (Orlando) Date: 2010-12-28 Impact factor: 3.943
Authors: David W Mudge; Bronwyn A Atcheson; Paul J Taylor; Peter I Pillans; David W Johnson Journal: Ther Drug Monit Date: 2004-08 Impact factor: 3.681
Authors: Dirk R J Kuypers; Yannick Le Meur; Marcelo Cantarovich; Michael J Tredger; Susan E Tett; Dario Cattaneo; Burkhard Tönshoff; David W Holt; Jeremy Chapman; Teun van Gelder Journal: Clin J Am Soc Nephrol Date: 2010-01-07 Impact factor: 8.237
Authors: Tanja R Zijp; Zamrotul Izzah; Daan J Touw; Job F M van Boven; Christoffer Åberg; C Tji Gan; Stephan J L Bakker Journal: Drugs Date: 2021-11-01 Impact factor: 9.546